| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 15, 2024 | HIMS Hims & Hers Health, Inc. | Boughton Soleil | Chief Legal Officer | Sell | 2,503 | $13.95 | $34,916.85 | -1.5% | +72.8% | +122.8% | |
| Apr 15, 2024 | LNTH Lantheus Holdings, Inc. | Sabens Andrea47 | Chief Accounting Officer | Sell | 341 | $61.24 | $20,882.84 | -0.5% | +104.5% | +70.6% | |
| Apr 15, 2024 | NBIX Neurocrine Biosciences Inc | Benevich Eric62 | Chief Commercial Officer | Sell | 19,818 | $133.36 | $2,643,019.64 | -19.5% | +11.9% | -27.0% | |
| Apr 12, 2024 | LQDA Liquidia Corp | Kaseta Michael57 | CFO And COO | Sell | 3,136 | $14.58 | $45,722.88 | -1.0% | -10.6% | -3.4% | |
| Apr 12, 2024 | LQDA Liquidia Corp | Schundler Russell58 | General Counsel | Sell | 2,060 | $14.58 | $30,034.80 | -0.4% | -10.6% | -3.4% | |
| Apr 12, 2024 | ANIP Ani Pharmaceuticals Inc | Cook Meredith49 | Sr. VP, General Counsel &Sec. | Sell | 250 | $67.79 | $16,947.50 | -0.4% | -3.9% | +1.9% | |
| Apr 12, 2024 | LQDA Liquidia Corp | Jeffs Roger66 | Chief Executive Officer | Sell | 8,360 | $14.58 | $121,888.80 | -1.0% | -10.6% | -3.4% | |
| Apr 12, 2024 | LQDA Liquidia Corp | Moomaw Scott | Chief Commercial Officer | Sell | 1,585 | $14.58 | $23,109.30 | -1.0% | -10.6% | -3.4% | |
| Apr 12, 2024 | LQDA Liquidia Corp | Saggar Rajeev | Chief Medical Officer | Sell | 1,525 | $14.58 | $22,234.50 | -0.7% | -10.6% | -3.4% | |
| Apr 12, 2024 | UTHR United Therapeutics Corp | Rothblatt Martine A58 | Chairperson &CEO | Sell | 7,200 | $237.19 | $1,707,775.42 | -35.0% | +39.2% | +20.9% | |
| Apr 12, 2024 | LQDA Liquidia Corp | Adair Jason | Chief Business Officer | Sell | 1,189 | $14.58 | $17,335.62 | -1.1% | -10.6% | -3.4% | |
| Apr 10, 2024 | UTHR United Therapeutics Corp | Rothblatt Martine A58 | Chairperson &CEO | Sell | 28,800 | $237.21 | $6,831,736.68 | -29.1% | +35.7% | +17.3% | |
| Apr 8, 2024 | UTHR United Therapeutics Corp | Rothblatt Martine A58 | Chairperson &CEO | Sell | 20,060 | $235.68 | $4,727,735.68 | -23.7% | +33.7% | +18.0% | |
| Apr 8, 2024 | HIMS Hims & Hers Health, Inc. | Baird Melissa | Chief Operating Officer | Sell | 35,253 | $14.74 | $519,558.71 | -1.1% | +37.8% | +75.4% | |
| Apr 4, 2024 | HIMS Hims & Hers Health, Inc. | Dudum Andrew48 | Chief Executive Officer | Sell | 333,332 | $14.89 | $4,962,693.33 | -9.7% | +39.6% | +77.0% | |
| Apr 4, 2024 | UTHR United Therapeutics Corp | Mahon Paul A47 | EVP &General Counsel | Sell | 6,000 | $232.37 | $1,394,248.25 | -3.0% | +33.0% | +25.0% | |
| Apr 4, 2024 | UTHR United Therapeutics Corp | Rothblatt Martine A58 | Chairperson &CEO | Sell | 30,000 | $231.92 | $6,957,709.48 | -31.1% | +33.0% | +25.0% | |
| Apr 4, 2024 | BTAI Bioxcel Therapeutics, Inc. | Wiley Matthew T.82 | Chief Commercial Officer | Sell | 1,008 | $2.64 | $2,656.18 | -25.2% | -59.9% | -96.2% | |
| Apr 4, 2024 | BTAI Bioxcel Therapeutics, Inc. | Steinhart Richard I87 | Chief Financial Officer | Sell | 1,069 | $2.64 | $2,816.81 | -18.3% | -59.9% | -96.2% | |
| Apr 4, 2024 | BTAI Bioxcel Therapeutics, Inc. | Rodriguez Javier87 | See Remarks | Sell | 1,012 | $2.64 | $2,667.43 | -11.7% | -59.9% | -96.2% | |
| Apr 4, 2024 | BTAI Bioxcel Therapeutics, Inc. | O'Neill Vincent86 | See Remarks | Sell | 165 | $2.62 | $432.48 | -3.0% | -59.9% | -96.2% | |
| Apr 4, 2024 | BTAI Bioxcel Therapeutics, Inc. | Mehta Vimal92 | CEO And President | Sell | 5,268 | $2.62 | $13,823.02 | -5.4% | -59.9% | -96.2% | |
| Apr 4, 2024 | BTAI Bioxcel Therapeutics, Inc. | Yocca Frank88 | Chief Scientific Officer | Sell | 1,067 | $2.64 | $2,811.54 | -7.7% | -59.9% | -96.2% | |
| Apr 2, 2024 | UTHR United Therapeutics Corp | Rothblatt Martine A58 | Chairperson &CEO | Sell | 30,000 | $228.69 | $6,860,825.07 | -23.4% | +39.6% | +36.6% | |
| Apr 1, 2024 | HIMS Hims & Hers Health, Inc. | Boughton Soleil | Chief Legal Officer | Sell | 2,503 | $15.65 | $39,171.95 | -1.5% | +36.8% | +98.3% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.